Announcement of Tibet Nuodikang Pharmaceutical Co., Ltd. on the shareholdings of the top ten shareholders and the top ten shareholders without selling restrictions on share repurchases
Securities code: 600211 Securities abbreviation: Tibet Pharmaceutical Announcement number: 2025-045
Tibet Nuodikang Pharmaceutical Co., Ltd.
Regarding the repurchase of shares, the top ten shareholders and the top ten shareholders without selling restrictions
Announcement of shareholding status
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
The company held the fourth extraordinary meeting of the eighth board of directors on December 18, 2025, and reviewed and approved the "Proposal on Repurchasing Shares through Centralized Bidding Transactions". For details, please refer to the company's announcement on December 19, 2025. The "Plan on Repurchasing Shares through Centralized Bidding Transactions" (announcement number: 2025-044) was published on the "China Securities Journal", "Shanghai Securities News", "Securities Times" and the Shanghai Stock Exchange website (www.sse.com.cn).
In accordance with the "Share Repurchase Rules of Listed Companies", "Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, the names, shareholding quantities and proportions of the top ten shareholders and the top ten shareholders without selling restrictions who were registered on the trading day before the company's board of directors announced the resolution to repurchase shares (i.e. December 18, 2025) are now announced as follows:
1. Shareholding status of the company’s top ten shareholders
No. Name of shareholder Number of shares held (shares) Proportion of total share capital of the company (%) Tibet Kangzhe Enterprise Management Co., Ltd. 104,043,393 32.28 Tibet Huaxi Pharmaceutical Group Co., Ltd. 56,148,300 17.42 Beijing New Phoenix Real Estate Development Co., Ltd. 10,283,000 3.19 Shenzhen Kangzhe Pharmaceutical Co., Ltd. 10,021,297 3.11 Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd. 6,339,438 1.97 Tibet Science and Technology Innovation Investment Co., Ltd. 6,199,000 1.92 Hong Kong Securities Clearing Company Limited 3,056,600 0.95 China International Finance Securities (Hong Kong) Co., Ltd. - Client Funds (Exchange) 2,408,925 0.75 Bank of Shanghai Co., Ltd. - Yinhua CSI Innovative Drug Industry
1,958,504 0.61 Exchange-traded open-end index securities investment fund
China Merchants Bank Co., Ltd.-South China Securities 1000 Trading Type
1,447,772 0.45 open-end index securities investment fund
2. Shareholding status of the company’s top ten shareholders without selling restrictions
No. Name of shareholder Number of shares held (shares) Proportion of total share capital of the company (%) Tibet Kangzhe Enterprise Management Co., Ltd. 104,043,393 32.28 Tibet Huaxi Pharmaceutical Group Co., Ltd. 56,148,300 17.42 Beijing New Phoenix Real Estate Development Co., Ltd. 10,283,000 3.19 Shenzhen Kangzhe Pharmaceutical Co., Ltd. 10,021,297 3.11 Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd. 6,339,438 1.97 Tibet Science and Technology Innovation Investment Co., Ltd. 6,199,000 1.92 Hong Kong Securities Clearing Company Limited 3,056,600 0.95 China International Finance Securities (Hong Kong) Co., Ltd. – Client Funds (Trading)
2,408,925 0.75)
Bank of Shanghai Co., Ltd.-Yinhua CSI Innovative Drug Industry
1,958,504 0.61 Exchange-traded open-end index securities investment fund
China Merchants Bank Co., Ltd.-South China Securities 1000 Trading Type
1,447,772 0.45 open-end index securities investment fund
Announcement is hereby made.
Tibet Nuodikang Pharmaceutical Co., Ltd.
December 25, 2025